Savor Health Addresses Unmet Medical Need: Nutrition for Patients With Cancer
March 28th 2019Ninety percent of patients with cancer enter their first oncology appointment with a nutritional issue, according to Susan Bratton. However, Savor Health, who works in conjunctions with Merck’s Your Cancer Game Plan, has set out to combat just that.
FDA Approves Assay to Determine Eligibility for Tecentriq in Triple-Negative Breast Cancer
March 11th 2019The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.
Oral Rivaroxaban Reduces VTE in Outpatient Treatment of Patients With Cancer
March 9th 2019Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.
cfDNA Proves Accurate Yet Faster Than Tissue Genotyping in NSCLC Biomarker Identification
March 1st 2019A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.
FDA Grants Priority Review to Polatuzumab Vedotin Combination for R/R DLBC
February 19th 2019The FDA granted a priority review to polatuzumab vedotin in combination with bendamustine plus rituximab (Rituxan) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
FDA Grants Priority Review to Entrectinib for NTRK+ Solid Tumors, ROS1+ NSCLC
February 19th 2019The FDA granted a priority review to entrectinib for the treatment of adult and pediatric patients with NTRK fusion-positive, locally advanced or metastatic solid tumors and for metastatic, ROS1-positive non-small cell lung cancer.
FDA Grants Priority Review to Frontline Pembro to Treat Recurrent, Metastatic HNSCC
February 11th 2019The FDA granted a priority review to the supplemental biologics license application for pembrolizumab (Keytruda) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS Anemia
December 12th 2018Treatment with luspatercept significantly reduced the need for frequent red blood cell transfusions in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome (MDS), according to results from the phase III Medalist trial presented at the 2018 ASH Annual Meeting.
Beat AML Trial Proves Feasibility of Rapid Treatment Assignment Following Diagnosis
December 8th 2018Hematologists may have the ability to determine acute myeloid leukemia (AML) subtype based on genetic analysis of blood samples in 7 days or less, a process that could soon be an integral part of diagnosing and treating this patient population, according to Amy Burd, PhD.
First HCT Following CAR T-Cell Therapy Reduces Risk for ALL Relapse
December 8th 2018Receiving a stem cell transplant for the first time following CD19 CAR T-cell therapy induced a reduction in the risk for acute lymphoblastic leukemia (ALL) recurrence, according to a retrospective analysis of the phase I/II PLAT-02 study.1
FDA Grants Atezolizumab Combo Priority Review for First-Line Use in SCLC
December 5th 2018The FDA has granted a priority review designation to atezolizumab (Tecentriq) for use in combination with carboplatin and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Tivozanib Improves Progression-Free Survival in Renal Cell Carcinoma
November 24th 2018Patients with renal cell carcinoma (RCC) who were treated with tivozanib (Fotivda) experienced a 26% reduction in the risk of progression or death compared with sorafenib (Nexavar), according to results from the phase 3 TIVO-3 trial.
FDA Grants Priority Review to Atezolizumab Combination for Metastatic TNBC Subset
November 13th 2018The Food and Drug Administration (FDA) granted a priority review to atezolizumab (Tecentriq) in combination with nab-paclitaxel (Abraxane) for frontline use in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose disease expresses the PD-L1 protein.
FDA Grants Priority Review to Ruxolitinib for Acute GVHD
October 27th 2018The Food and Drug Administration has granted a priority review to the supplemental new drug application for ruxolitinib (Jakafi) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.
Adding Durvalumab to Chemoradiation Improves OS in Unresectable Stage III NSCLC
October 4th 2018Durvalumab (Imfinzi) induced a clinically meaningful improvement in overall survival (OS) compared with placebo in patients with stage III, unresectable non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.
Brigatinib Bests Standard of Care to Improve PFS in Advanced NSCLC
October 2nd 2018Brigatinib (Alunbrig) reduced the risk of disease progression or death by more than 50% compared to crizotinib (Xalkori) in adult patients with ALK-positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor.